Evidence map›Paper›PMID 30457566›Full record

ArticleScientific data2018

Combined RNA-seq and RAT-seq mapping of long noncoding RNAs in pluripotent reprogramming.

Zhonghua Du, Lin Jia, Yichen Wang, Cong Wang, Xue Wen, Jingcheng Chen, Yanbo Zhu, Dehai Yu, Lei Zhou, Naifei Chen and 9 more

Open access · goldAbstract readDataset
In one paragraph

Article in Scientific data, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. International journal of molecular medicine · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. International journal of biological sciences · 2020
    Article
  13. Review
  14. Article
  15. Article
  16. Genome-wide target interactome profiling reveals a novelAmerican journal of cancer research · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 2 countries.

Zhonghua DuStem Cell and Cancer Center, First Hospital, Jilin University, Changchun, Jilin 130061, P.R. China.
Lin JiaStem Cell and Cancer Center, First Hospital, Jilin University, Changchun, Jilin 130061, P.R. China.
Yichen WangStem Cell and Cancer Center, First Hospital, Jilin University, Changchun, Jilin 130061, P.R. China.
Cong WangStem Cell and Cancer Center, First Hospital, Jilin University, Changchun, Jilin 130061, P.R. China.
Xue WenStem Cell and Cancer Center, First Hospital, Jilin University, Changchun, Jilin 130061, P.R. China.
Jingcheng ChenStem Cell and Cancer Center, First Hospital, Jilin University, Changchun, Jilin 130061, P.R. China.
Yanbo ZhuStem Cell and Cancer Center, First Hospital, Jilin University, Changchun, Jilin 130061, P.R. China.
Dehai YuStem Cell and Cancer Center, First Hospital, Jilin University, Changchun, Jilin 130061, P.R. China.
Lei ZhouStem Cell and Cancer Center, First Hospital, Jilin University, Changchun, Jilin 130061, P.R. China.
Naifei ChenStem Cell and Cancer Center, First Hospital, Jilin University, Changchun, Jilin 130061, P.R. China.
Shilin ZhangStem Cell and Cancer Center, First Hospital, Jilin University, Changchun, Jilin 130061, P.R. China.
Ilkay CelikStanford University Medical School, VA Palo Alto Health Care System, Palo Alto, CA 94304, USA.
Ferhat AyLa Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA.ORCID 0000-0002-0708-6914
Sujun GaoStem Cell and Cancer Center, First Hospital, Jilin University, Changchun, Jilin 130061, P.R. China.
Songling ZhangStem Cell and Cancer Center, First Hospital, Jilin University, Changchun, Jilin 130061, P.R. China.
Wei LiStem Cell and Cancer Center, First Hospital, Jilin University, Changchun, Jilin 130061, P.R. China.
Andrew R HoffmanStanford University Medical School, VA Palo Alto Health Care System, Palo Alto, CA 94304, USA.
Jiuwei CuiStem Cell and Cancer Center, First Hospital, Jilin University, Changchun, Jilin 130061, P.R. China.
Ji-Fan HuStem Cell and Cancer Center, First Hospital, Jilin University, Changchun, Jilin 130061, P.R. China.
Jilin University · CNVA Palo Alto Health Care System · USLa Jolla Institute for Immunology · US

Funding

The Role of Long Noncoding RNAs in CancerI01BX002905 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI HOFFMAN, ANDREW R · 2016 to 2023
–
BLRD VA I01 BX002905
6 · The paper itself

Abstract

Pluripotent stem cells hold great investigative potential for developmental biology and regenerative medicine. Recent studies suggest that long noncoding RNAs (lncRNAs) may function as key regulators of the maintenance and the lineage differentiation of stem cells. However, the underlying mechanisms by which lncRNAs affect the reprogramming process of somatic cells into pluripotent cells remain largely unknown. Using fibroblasts and induced pluripotent stem cells (iPSCs) at different stages of reprogramming, we performed RNA transcriptome sequencing (RNA-Seq) to identify lncRNAs that are differentially-expressed in association with pluripotency. An RNA reverse transcription-associated trap sequencing (RAT-seq) approach was then utilized to generate a database to map the regulatory element network for lncRNA candidates. Integration of these datasets can facilitate the identification of functional lncRNAs that are associated with reprogramming. Identification of lncRNAs that regulate pluripotency may lead to new strategies for enhancing iPSC induction in regenerative medicine.

Indexed as

Pluripotent Stem CellsRNA, Long NoncodingTranscriptomeCell DifferentiationCellular ReprogrammingFibroblastsHumansInduced Pluripotent Stem CellsSequence Analysis, RNARNA, Long Noncoding

Identifiers

PMID30457566
PMCPMC6244186
OpenAlexW2901530972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.